This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
This week, we will discuss the HOPE trial - no not that one - the one in dialysis that was a LBCT in 2024. Should we look beyond analgesics to non-pharmacological options more seriously?
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
What the hell is CHIP and why do I need to know about it?
Check out this rapid summary by the talented and creative Tiffany Caza!
Did you miss the last #NephJC? Check out this #TenTweetNephJC to catch up! pic.twitter.com/7oT34h2vzx
— Nephrology Jrnl Club (@NephJC) May 24, 2022
NSMC intern Mohamed Ibrahim created a beautiful visual abstract which simplifies the findings of CHIP study.
